Breaking News

Tweet TWEET

Affymetrix Signs Contract With UK Biobank to Genotype 500,000 UK Individuals in the Largest Ever Study of Genetic and

  Affymetrix Signs Contract With UK Biobank to Genotype 500,000 UK Individuals
  in the Largest Ever Study of Genetic and Environmental Factors in Disease
  and Personalized Medicine

Business Wire

SANTA CLARA, Calif. -- March 22, 2013

Affymetrix, Inc. (NASDAQ: AFFX) today announced that it has signed a contract
with UK Biobank to genotype 500,000 DNA samples donated by UK residents as
part of a prospective epidemiological study of complex diseases that are of
great relevance to public health. Affymetrix’ Axiom^® Genotyping Solution will
be used to generate billions of high-quality genotypes which will provide UK
Biobank and the research community with valuable insight to genetic factors
underlying human diseases for improved prevention, diagnosis, and treatment of
conditions such as heart disease, cancer, and diabetes.

Professor Rory Collins, UK Biobank CEO and Principal Investigator said: “UK
Biobank is pleased to join forces with Affymetrix for this next phase of the
UK Biobank project. The two organizations will work closely together to ensure
that world class data are provided quickly and securely to help scientists
working on the causes of a wide range of life-threatening and disabling
diseases. I urge health scientists everywhere to think carefully about how
this resource could be used to help their research, and to register with UK
Biobank. I am also very grateful to the half a million participants whose
generosity and vision for the future has allowedthis resource to grow.”

“We are honored to partner with UK Biobank on this mission critical research
initiative,” said Dr. Frank Witney, President and CEO of Affymetrix. “Earlier
this year, we outlined our strategy to broaden our reach into the
translational medicine, molecular diagnostics, and applied markets as part of
our long-term transformation plan. This partnership reflects our efforts to
strengthen our position in the growing translational medicine market and our
commitment to work with visionary organizations such as the UK Biobank to
produce the next generation of biological information that will improve
healthcare.”

“Large scale genotyping studies such as the one undertaken by UK Biobank
demand a flexible and scalable genomics analysis technology that produces a
large amount of high quality data quickly, consistently, and cost-effectively.
The unmatched flexibility, array reproducibility, and advanced design
capabilities were key factors in UK Biobank adopting the Axiom Genotyping
Solution. These platform capabilities have become increasingly important for
genotyping studies in both the human and agbio markets as requirements shift
away from very high-density, standardized designs toward customized
high-fidelity arrays. We are very proud that our Axiom Genotyping Solution has
been chosen for this incredibly important project,” said Dr. Andy Last, EVP
and General Manager of Genetic and Clinical Applications at Affymetrix.

Affymetrix expects to begin delivering data for the study towards the end of
2013. Affymetrix does not expect revenue from this contract to have a material
impact in 2013, as it will start to recognize revenue in the latter part of
this year, with the majority of the revenue expected to be recognized in 2014.

About UK Biobank:

UK Biobank is a major national health resource, and a registered charity in
its own right, with the aim of improving the prevention, diagnosis and
treatment of a wide range of serious and life-threatening illnesses –
including cancer, heart diseases, stroke,diabetes, arthritis, osteoporosis,
eye disorders,depressionand forms of dementia.UK Biobank recruited500,000
people aged between 40-69 years in 2006-2010 from across the country to take
part in this project. They have undergone measures, provided blood, urine and
saliva samples for future analysis, detailed information about themselves and
agreed to have their health followed. Over many years this will build into a
powerful resource to help scientists discover why some people develop
particular diseases and others do not.

About Affymetrix

Affymetrix’ technologies are used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading academic,
government, and non-profit research institutes. More than 2,300 microarray
systems have been shipped around the world and more than 48,000 peer-reviewed
papers have been published citing our technologies. Affymetrix is
headquartered in Santa Clara, California, and has manufacturing facilities in
Cleveland, Ohio, San Diego, Vienna and Singapore. The Company has about 1,100
employees worldwide and maintains sales and distribution operations across
Europe, Asia, and Latin America. For more information about Affymetrix, please
visit www.affymetrix.com.

To learn more about Axiom Genotyping Solutions for human biobanks and other
large sample collections, please visit www.affymetrix.com/axiombiobank.

PLEASE NOTE: Affymetrix^®, the Affymetrix logo, Axiom^®, GeneTitan^® and all
other trademarks are the property of Affymetrix, Inc. All other trademarks are
the property of their respective owners.

Products mentioned in this release are for research use only. Not for
diagnostic procedures.

SOURCE: Affymetrix, Inc.

Forward-looking statements

All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or the like.
Such statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the year ended
December 31, 2012, and other Securities and Exchange Commission reports for
subsequent quarterly periods and include but not limited to (1) risks relating
to Affymetrix’ ability to perform its obligations under the contract, such as
delays in the receipt of samples, and (2) risks that the contract could
terminate early.

Contact:

Affymetrix, Inc.
Media Contact:
Mindy Lee-Olsen, + 1 408-731-5523
Vice President, Marketing Services
mindy_lee-olsen@affymetrix.com
or
Investor Contact:
Doug Farrell, +1 408-731-5285
Vice President, Investor Relations
doug_farrell@affymetrix.com
or
UK Biobank
Media Contact:
Andrew Trehearne, +44 1865 743960
Head of Communications
andrew.trehearne@ukbiobank.ac.uk
 
Press spacebar to pause and continue. Press esc to stop.